版本:
中国

BRIEF-Cytokinetics announces orphan drug designation for CK-2127107 for treatment of spinal muscular atrophy

May 15 Cytokinetics Inc

* Cytokinetics announces orphan drug designation for CK-2127107 for the treatment of spinal muscular atrophy

* Expects to see results from its ongoing phase 2 clinical trial for ck-2127107 later this year Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐